ABT shares hold steady near support levels as RSI approaches extreme lows: weekly report

Traders Union
All News
Financial News
Abbott Laboratories falls 1.16% this week

Highlights

Abbott (ABT) trades well below key moving averages, underscoring persistent selling pressure and negative momentum.
Weekly technical indicators collectively signal oversold conditions, with bearish momentum confirmed across multiple trend and momentum measures.
For the next week, price is expected to remain between $84.25 and $88.60, with downside risk dominating if $84.25 is breached.

Stable financials and dividend outlook offset by nutrition headwinds and strategic updates

Abbott reported stable financial performance, with a 2.88% dividend yield supported by a 67.23% payout ratio, earnings per share of 3.57, and free cash flow above $6.3 billion. The company continues to face headwinds in its nutrition segment, while maintaining a strong overall market position. Abbott is preparing to showcase 11 studies in its cancer diagnostics portfolio at the upcoming ASCO Annual Meeting and has updated its 2026 guidance following the acquisition of Exact Sciences.

Persistent bearish momentum as key indicators confirm oversold weekly conditions

Weekly technical analysis shows ABT trading significantly below all major moving averages, with the MA-20 at $104.03 acting as dynamic resistance. Strong downside momentum persists, reflected in negative MACD and ADX readings, with RSI near 24, Stochastic RSI, and CCI all pointing to heavily oversold conditions. Bearish dominance is evident on the Bull/Bear Power and Awesome Oscillator, confirming a persistently negative bias. Key levels for the week are support at $84.25 and resistance at $88.60.

Sideways trade favored as lack of bullish signals limits rebound potential

Over the next 5 trading days, ABT is likely to move sideways within the $84.25 to $88.60 range as recent volatility remains modest. The probability of a sustained rebound is low, given the lack of any bullish signals on weekly indicators; continued downward pressure and relative weakness are expected. A bullish breakout above $88.60 could spark a brief short-term recovery, though technical signals do not support this scenario. More likely, a sustained break below $84.25 would enable further downside, with sellers retaining control.

Earlier, analysts noted that Abbott Laboratories was experiencing persistent bearish momentum, with technical pressures outweighing pockets of fundamental strength. The current analysis reinforces this view, with fresh evidence of entrenched downside bias and the risk that a decisive break below $84.25 could trigger an acceleration of selling pressure.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.